Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 4/20 | 0.48 |
| ▸ | NR1I2 | O75469 | 4/20 | 0.47 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.44 |
| ▸ | EDNRB | P24530 | 2/20 | 0.44 |
| ▸ | EDNRA | P25101 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALDH3A1 | P30838 | 2/20 | 0.42 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
| ▸ | CCR4 | P51679 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL617451 | 0.91 | HSD11B1 (0.48) | HSD11B1NR1I2SLC40A1EDNRBEDNRA | |
| SCHEMBL615397 | 0.87 | HSD11B1 (0.50) | HSD11B1NR1I2SLC40A1EDNRBEDNRA | |
| SCHEMBL12945240 | 0.85 | NR1I2 (0.45) | HSD11B1NR1I2SLC40A1EDNRBEDNRA | |
| SCHEMBL615834 | 0.84 | KDM4E (0.49) | HSD11B1NR1I2SLC40A1EDNRBEDNRA | |
| SCHEMBL617253 | 0.81 | HSD11B1 (0.45) | HSD11B1NR1I2SLC40A1EDNRBEDNRA | |
| SCHEMBL13248534 | 0.81 | HSD11B1 (0.45) | HSD11B1NR1I2SLC40A1EDNRBEDNRA | |
| SCHEMBL615027 | 0.81 | HSD11B1 (0.45) | HSD11B1NR1I2SLC40A1EDNRBEDNRA | |
| SCHEMBL616427 | 0.81 | NR1I2 (0.56) | HSD11B1NR1I2EDNRAGSPT1DDB1 | |
| SCHEMBL616054 | 0.80 | NPC1 (0.53) | HSD11B1NR1I2SLC40A1EDNRBEDNRA | |
| SCHEMBL27633512 | 0.80 | HSD11B1 (0.41) | HSD11B1NR1I2SLC40A1EDNRBEDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120041207-A1 | Compound | STERIX LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| US-20110009448-A1 | Compound | STERIX LIMITED | 2011-01-13 | — | — | US | disclosed |
| US-7786152-B2 | Compound | STERIX LIMITED (GB) | 2010-08-31 | — | — | US | disclosed |
| US-20080114042-A1 | Inhibiting 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD); use of sulfonamide-substituted N-heterocyclics including pyrroles, oxazoles, thiazoles, imidazoles and their fused analogs to treat diabetes, obesity, hypertension, arthritis, asthma, osteoporosis, breast cancer | STERIX LIMITED (GB) | 2008-05-15 | — | — | US | disclosed |
| US-7309715-B2 | Compound | STERIX LIMITED (GB) | 2007-12-18 | — | — | US | disclosed |
| EP-1556040-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 AND TYPE 2 | Sterix Limited (GB) | 2005-07-27 | — | — | EP | disclosed |
| US-20040143124-A1 | Compound | STERIX LIMITED (GB) | 2004-07-22 | — | — | US | disclosed |
| WO-2004037251-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 AND TYPE 2 | STERIX LIMITED (GB) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114042-A1 | Inhibiting 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD); use of sulfonamide-substituted N-heterocyclics including pyrroles, oxazoles, thiazoles, imidazoles and their fused analogs to treat diabetes, obesity, hypertension, arthritis, asthma, osteoporosis, breast cancer | HSD11B1, HSD3B1, HSD11B2 | HSD11B1 1/4885NR1I2 84/4885SLC40A1 4441/4885 |
| US-20110009448-A1 | Compound | NR4A1, GPR6, PRMT6 | HSD11B1 331/4885NR1I2 90/4885SLC40A1 3111/4885 |
| US-20120041207-A1 | Compound | NR4A1, GPR6, PRMT6 | HSD11B1 331/4885NR1I2 90/4885SLC40A1 3111/4885 |
| US-20040143124-A1 | Compound | NR4A1, CBR1, NR2C2 | HSD11B1 192/4885NR1I2 49/4885SLC40A1 2902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.